Arcoma AB (ARCOMA.ST)
SEK 10.95
(3.3%)
SEK 10.95
(3.3%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 2.56 Million SEK | 34.81% |
| 2022 | 1.9 Million SEK | 125.45% |
| 2021 | -7.47 Million SEK | -647.47% |
| 2020 | 1.36 Million SEK | -79.35% |
| 2019 | 6.61 Million SEK | 516.77% |
| 2018 | -1.58 Million SEK | 83.85% |
| 2017 | -9.82 Million SEK | 15.68% |
| 2016 | -11.64 Million SEK | -80.59% |
| 2015 | -6.44 Million SEK | -805.58% |
| 2014 | 914 Thousand SEK | 107.86% |
| 2013 | -11.62 Million SEK | -260.25% |
| 2012 | -3.22 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 3.65 Million SEK | -18.77% |
| 2024 Q3 | 2.3 Million SEK | -37.02% |
| 2024 Q1 | 4.5 Million SEK | 78.79% |
| 2023 Q3 | 1.97 Million SEK | 389.6% |
| 2023 Q1 | -2.77 Million SEK | -1196.84% |
| 2023 FY | 2.56 Million SEK | 34.81% |
| 2023 Q4 | 2.51 Million SEK | 27.3% |
| 2023 Q2 | 404 Thousand SEK | 114.56% |
| 2022 Q1 | -1.45 Million SEK | 80.02% |
| 2022 FY | 1.9 Million SEK | 125.45% |
| 2022 Q4 | 253 Thousand SEK | -82.58% |
| 2022 Q2 | 996 Thousand SEK | 168.45% |
| 2022 Q3 | 1.45 Million SEK | 45.78% |
| 2021 Q1 | 1.87 Million SEK | 131.4% |
| 2021 Q4 | -7.28 Million SEK | -135.85% |
| 2021 Q2 | 1.02 Million SEK | -45.14% |
| 2021 Q3 | -3.08 Million SEK | -400.68% |
| 2021 FY | -7.47 Million SEK | -647.47% |
| 2020 Q2 | 2.3 Million SEK | -42.07% |
| 2020 Q1 | 3.97 Million SEK | 390.01% |
| 2020 Q3 | 1.05 Million SEK | -54.39% |
| 2020 Q4 | -5.96 Million SEK | -667.71% |
| 2020 FY | 1.36 Million SEK | -79.35% |
| 2019 Q2 | 2.48 Million SEK | 277.51% |
| 2019 Q4 | 811 Thousand SEK | -69.48% |
| 2019 Q3 | 2.65 Million SEK | 6.96% |
| 2019 Q1 | 658 Thousand SEK | 191.26% |
| 2019 FY | 6.61 Million SEK | 516.77% |
| 2018 Q4 | -721 Thousand SEK | -1176.12% |
| 2018 FY | -1.58 Million SEK | 83.85% |
| 2018 Q3 | 67 Thousand SEK | -90.82% |
| 2018 Q2 | 730 Thousand SEK | 143.92% |
| 2018 Q1 | -1.66 Million SEK | -715.56% |
| 2017 Q1 | -1 Million SEK | -163.84% |
| 2017 FY | -9.82 Million SEK | 15.68% |
| 2017 Q4 | 270 Thousand SEK | 104.86% |
| 2017 Q3 | -5.55 Million SEK | -57.42% |
| 2017 Q2 | -3.53 Million SEK | -251.94% |
| 2016 FY | -11.64 Million SEK | -80.59% |
| 2016 Q4 | 1.57 Million SEK | 292.05% |
| 2016 Q3 | -818 Thousand SEK | 82.14% |
| 2016 Q2 | -4.58 Million SEK | 41.28% |
| 2016 Q1 | -7.8 Million SEK | -916.0% |
| 2015 Q1 | 701 Thousand SEK | -50.7% |
| 2015 Q2 | -6.15 Million SEK | -977.75% |
| 2015 Q3 | -1.95 Million SEK | 68.28% |
| 2015 FY | -6.44 Million SEK | -805.58% |
| 2015 Q4 | 956 Thousand SEK | 148.98% |
| 2014 Q1 | 489 Thousand SEK | 111.46% |
| 2014 Q2 | -204 Thousand SEK | -141.72% |
| 2014 Q3 | -764 Thousand SEK | -274.51% |
| 2014 Q4 | 1.42 Million SEK | 286.13% |
| 2014 FY | 914 Thousand SEK | 107.86% |
| 2013 Q3 | -1.78 Million SEK | 0.0% |
| 2013 FY | -11.62 Million SEK | -260.25% |
| 2013 Q4 | -4.26 Million SEK | -138.71% |
| 2012 FY | -3.22 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.83 Million SEK | 103.294% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 97.523% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 97.523% |
| Bactiguard Holding AB (publ) | -138.38 Million SEK | 101.853% |
| BICO Group AB (publ) | -835.7 Million SEK | 100.307% |
| Boule Diagnostics AB (publ) | 24.97 Million SEK | 89.735% |
| CellaVision AB (publ) | 130.3 Million SEK | 98.032% |
| Clinical Laserthermia Systems AB (publ) | -79.79 Million SEK | 103.213% |
| Chordate Medical Holding AB (publ) | -29.18 Million SEK | 108.785% |
| C-Rad AB (publ) | 35.52 Million SEK | 92.783% |
| Duearity AB (publ) | -26.19 Million SEK | 109.79% |
| Dignitana AB (publ) | -17.36 Million SEK | 114.767% |
| Episurf Medical AB (publ) | -94.8 Million SEK | 102.705% |
| Getinge AB (publ) | 2.41 Billion SEK | 99.894% |
| Scandinavian Real Heart AB (Publ) | -67.97 Million SEK | 103.772% |
| Iconovo AB (publ) | -45.89 Million SEK | 105.587% |
| Integrum AB (publ) | 4.03 Million SEK | 36.416% |
| Luxbright AB (publ) | -25.37 Million SEK | 110.104% |
| Mentice AB (publ) | -2.81 Million SEK | 191.019% |
| OssDsign AB (publ) | -130.49 Million SEK | 101.965% |
| Paxman AB (publ) | 8.33 Million SEK | 69.22% |
| Promimic AB (publ) | -9.22 Million SEK | 127.803% |
| Qlife Holding AB (publ) | -159.95 Million SEK | 101.603% |
| SciBase Holding AB (publ) | -55.58 Million SEK | 104.613% |
| ScandiDos AB (publ) | -14.64 Million SEK | 117.505% |
| Sectra AB (publ) | 428.38 Million SEK | 99.401% |
| Sedana Medical AB (publ) | -59.61 Million SEK | 104.301% |
| Senzime AB (publ) | -134.14 Million SEK | 101.911% |
| SpectraCure AB (publ) | -20.44 Million SEK | 112.543% |
| Stille AB | 26.64 Million SEK | 90.378% |
| Vitrolife AB (publ) | -3.85 Billion SEK | 100.067% |
| Xvivo Perfusion AB (publ) | 91.82 Million SEK | 97.208% |